Enveric Biosciences Inc vs Seagate Technology Holdings PLC — how do they compare? Enveric Biosciences Inc trades at $1.39 (market cap $5.32M), while Seagate Technology Holdings PLC trades at $753.6 (market cap $187.40B). The key difference: Seagate Technology Holdings PLC is far larger — about 35225.6× Enveric Biosciences Inc's market cap, and Seagate Technology Holdings PLC pays a 0.36% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | STX | |
|---|---|---|
Market Cap | $5.32M | $187.40B |
Sector | Health | Technology |
52-Week High | $17.40 | $1.09K |
52-Week Low | $1.28 | $146.59 |
Enterprise Value | $408.82K | $190.44B |
Dividend Yield | — | 0.36% |
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Seagate Technology (STX) trades at $878.31, up 2.05% with strong recent earnings beats and bullish analyst sentiment. The stock shows robust fundamentals with 21.6% net margins and 96.27% ROE, though valuation metrics appear elevated with P/E at 78.59. Technical indicators are neutral overall with support at $866 and resistance at $893, while the company benefits from AI-driven storage demand and positive industry outlook.
Outlook remains positive with 54.9% analyst buy ratings and $987.86 consensus target, representing 12.5% upside. Key risks include high debt levels (73.31% debt-to-asset ratio) and competitive pressures in the memory sector. The upcoming Q2 earnings report on July 28, 2026, with expected EPS of $5.10, will be critical for near-term direction.
Trailing returns across standard periods
Latest headlines on both assets
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →